CARM Overview

Delisting Announcement: Carisma Therapeutics Inc. has announced its intention to voluntarily delist its common stock from Nasdaq and deregister under the Securities Exchange Act of 1934, following a determination of noncompliance with Nasdaq listing requirements.

Trading Transition: The company's common stock was suspended from trading on Nasdaq on October 13, 2025, and has since begun trading on the OTCID market under the symbol "CARM."

Timeline for Delisting: Carisma plans to file a Form 25 with the SEC around December 15, 2025, with the formal delisting expected to take effect by December 25, 2025, followed by a Form 15 filing to suspend reporting obligations.

Company Background: Carisma Therapeutics is a biotechnology firm focused on macrophage engineering for treating serious diseases, and it is currently winding down its operations.

Alphabet Inc. Stock Surge: Shares of Alphabet Inc. rose 5.8% in pre-market trading after a U.S. judge ruled that Google does not need to divest its Android operating system or sell Google Chrome in the ongoing online search monopoly case.

Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, with Solidion Technology, Inc. gaining 130.1%, while SmartKem, Inc. saw a decline of 21.4% after a previous surge.

U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling over 1%, while the NASDAQ and S&P 500 also experienced significant drops. Notable movements included a 2% decrease in NIO shares following disappointing quarterly results, despite a year-over-year revenue increase.

Sector and Commodity Updates: Consumer staples saw a slight increase, while information technology stocks fell. In commodities, oil and gold prices rose, and European and Asian markets mostly closed lower, reflecting a broader trend of declining equities globally.